MedTrace Logo

Prostate Artery Embolization for the Treatment of Benign Prostatic Hyperplasia

NCT03179228 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2017-10-17

No results posted yet for this study

Summary

The primary study objective is to evaluate improvement of symptoms from benign prostatic hyperplasia (BPH) as assessed by the International Prostate Symptom Score (IPSS) at 12 months post prostatic artery embolization (PAE) with bland microspheres.

Conditions

  • Prostatic Hyperplasia

Interventions

DEVICE

Prostate Embolization

Embolization of the prostate with acrylic polymer microspheres impregnated with porcine gelatin

Sponsors & Collaborators

  • John D Louie

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-10-14
Primary Completion
2023-06-01
Completion
2028-06-01
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03179228 on ClinicalTrials.gov